Publications
Rea D. EXABS-157-CML Immunotherapy: The Way Forward to Maximize TFR. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S64. doi: 10.1016/S2152-2650(22)00664-4. PMID: 36164234.
Dahlén T, Edgren G, Ljungman P, Flygt H, Richter J, Olsson-Strömberg U, Wadenvik H, Dreimane A, Myhr-Eriksson K, Zhao J, Själander A, Höglund M, Stenke L. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study. Am J Hematol. 2022 Apr;97(4):421-430. doi: 10.1002/ajh.26463. Epub 2022 Jan 20. PMID: 35015312; PMCID: PMC9306877.
Soverini S, De Santis S, Martelli M, Monaldi C, Castagnetti F, Gugliotta G, Papayannidis C, Mancini M, Bruno S, Venturi C, Machova Polakova K, Ernst T, Maar D, Corner A, Cavo M. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia. Leukemia. 2022 Sep;36(9):2250-2260. doi: 10.1038/s41375-022-01660-8. Epub 2022 Jul 30. PMID: 35908105.
Roy L, Chomel JC, Guilhot J, Guerci-Bresler A, Escoffre-Barbe M, Giraudier S, Charbonnier A, Dubruille V, Huguet F, Johnson-Ansah H, Lenain P, Ame S, Etienne G, Nicolini FE, Rea D, Cony-Makhoul P, Courby S, Ianotto JC, Legros L, Machet A, Coiteux V, Hermet E, Cayssials E, Bouchet S, Mahon FX, Rousselot P, Guilhot F; French CML Group (FiLMC). Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study). Br J Haematol. 2023 Jan;200(2):175-186. doi: 10.1111/bjh.18486. Epub 2022 Oct 10. PMID: 36214090.
Robertson HF, Apperley JF. Treatment of CML in pregnancy. Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):123-128. doi: 10.1182/hematology.2022000330. PMID: 36485083; PMCID: PMC9821432.
Chalandon Y, Sbianchi G, Gras L, Koster L, Apperley J, Byrne J, Salmenniemi U, Sengeloev H, Aljurf M, Helbig G, Kinsella F, Choi G, Reményi P, Snowden JA, Robin M, Lenhoff S, Mielke S, Passweg J, Broers AEC, Kröger N, Yegin ZA, Tan SM, Hayden PJ, McLornan DP, Yakoub-Agha I; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT. Am J Hematol. 2023 Jan;98(1):112-121. doi: 10.1002/ajh.26764. Epub 2022 Oct 31. PMID: 36266607.
Claudiani S, Janssen JJWM, Byrne J, Smith G, Blijlevens N, Raghavan M, Smith M, Clark RE, Mclain-Smith S, Carter AM, Milojkovic D, Apperley JF. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. Eur J Haematol. 2022 Jul;109(1):90-99. doi: 10.1111/ejh.13775. Epub 2022 May 17. PMID: 35403752; PMCID: PMC9321569.
Claudiani S, Parker EL, Milojkovic D, Rosadas C, Khan A, Katsanovskaja K, Marchesin F, Khan M, Tedder RS, Innes AJ, McClure MO, Apperley JF. Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study. Leuk Lymphoma. 2022 Jun;63(6):1504-1507. doi: 10.1080/10428194.2022.2027403. Epub 2022 Jan 24. PMID: 35068289.
Claudiani S, Apperley JF, Parker EL, Marchesin F, Katsanovskaja K, Palanicawandar R, Innes AJ, Tedder RS, McClure MO, Milojkovic D. Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. Br J Haematol. 2022 Apr;197(1):e1-e4. doi: 10.1111/bjh.18001. Epub 2021 Dec 19. PMID: 34923623.
Bencomo-Alvarez A, Rubio A, Olivas I, Gonzalez M, Ellwood R, Ripoll Fiol C, Eide C, Lara J, Barreto-Vargas C, Jave-Suarez L, Nteliopoulos G, Reid A, Milojkovic D, Druker B, Apperley JF, Khorashad J, Eiring A.. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene 2021 40:2697-2710 doi: 10.1038/s41388-021-01732-6
Branford S, Apperley JF. Measurable residual disease in chronic myeloid leukemia. Haematologica 2022 107:2794-2809. doi: 10.3324/haematol.2022.281493
Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C, J Innes A, Dominy K, Foskett P, Foroni L, Khorashad J, Milojkovic D. TKI dose reduction can effectively maintain major molecular remissions in patients with chronic myeloid leukaemia. Brit J Haem 2021 193:346-355 doi: 10.1111/bjh.17286
Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Advances 2021 5:1102-110 doi: 10.1182/bloodadvances.2020003570
Clark RE, Basabrain AA, Austin GM, Holcroft AK, Loaiza S, Apperley JF, Law C, Scott L, Parry AD, Bonnett L, Lucas CM. Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. Cancers 2021 13: 2155-2167 doi: 10.3390/cancers13092155.
Dominy K, O’Hare M, Szydlo R, Claudiani S, Foskett P, Foroni L, Milojkovi Dc, Apperley JF, Khorashad JS. Assessment of quantitative PCR for BCR-ABL1 transcripts in CML: are improved outcomes in patients with e14a2 transcripts an artefact of technology? British Journal of Haematology 2021 197:52-62. doi: 10.1111/bjh.18026.
Fernando F, Innes AJ, Claudiani S, Pryce A, Hayden C, Byrne J, Gallipoli P, Copland M, Apperley JF, Milojkovic D. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia Bone Marrow Transplant 2022 [EPub ahead of print]
Gallipolli P, Clark RE, Byrne J, Milojkovic D, Apperley JF, Foronii L, Goldman JM, O’Brien S.The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML) Brirish Journal of Haematology 2022 196:e55-e57
Khoury J, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Cheung Chan JK, Chen W, Chen X, Chng WJ, Choi J, Colmenero I, Coupland S, Cross NCP, de Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen J, Kanagal-Shamanna R, Kantarjian H, Kratz C, Li X, Lim M, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh K, Natkunam , Nejati R, Ott G, Padron E, Patel K, Patel K, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus A. 5th Edition of The World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 36: 1703–1719 doi: 10.1038/s41375-022-01613-1..
Milojkovic D, Mūnoz Sandoval D, Pieper FP, Liu S, Reynolds CJ, Pade C, Gibbons JM. McKnight A, Loaiza S, Palanicawander R, Innes AJ, Claudiani S, Apperley JF, Altmann DM, Boyton RJ. Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors show impaired cross-protective B cell memory to B.1.1.529 (Omicron). Leukemia 2023 37:244-247. doi: 10.1038/s41375-022-01787-8.
Loncarevic IF, Toepfer S, Hubold S, Klingner S, Kanitz L, Ellinger T, Steinmetzer K, Ernst T, Hochhaus A, Ermantraut E. Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads. PLoS One. 2021 Mar 18;16(3):e0242529. doi: 10.1371/journal.pone.0242529. PMID: 33735175; PMCID: PMC7971518.
Hochhaus A, Ernst T. TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission? Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):106-112. doi: 10.1182/hematology.2021000238. PMID: 34889388; PMCID: PMC8791110.
White HE, Salmon M, Albano F, Andersen CSA, Balabanov S, Balatzenko G, Barbany G, Cayuela JM, Cerveira N, Cochaux P, Colomer D, Coriu D, Diamond J, Dietz C, Dulucq S, Engvall M, Franke GN, Gineikiene-Valentine E, Gniot M, Gómez- Casares MT, Gottardi E, Hayden C, Hayette S, Hedblom A, Ilea A, Izzo B, Jiménez-Velasco A, Jurcek T, Kairisto V, Langabeer SE, Lion T, Meggyesi N, Mešanović S, Mihok L, Mitterbauer-Hohendanner G, Moeckel S, Naumann N, Nibourel O, Oppliger Leibundgut E, Panayiotidis P, Podgornik H, Pott C, Rapado I, Rose SJ, Schäfer V, Touloumenidou T, Veigaard C, Venniker-Punt B, Venturi C, Vigneri P, Vorkinn I, Wilkinson E, Zadro R, Zawada M, Zizkova H, Müller MC, Saussele S, Ernst T, Machova Polakova K, Hochhaus A, Cross NCP. Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia. 2022 Jul;36(7):1834-1842. doi: 10.1038/s41375-022-01607-z. Epub 2022 May 25. PMID: 35614319; PMCID: PMC9252906.
Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia. 2022 Jul;36(7):1879-1886. doi: 10.1038/s41375-022-01612-2. Epub 2022 Jun 8. PMID: 35676453; PMCID: PMC9252903.
Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, Fabisch C, Brümmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28. PMID: 35902731; PMCID: PMC9417980.
Hehlmann R, Lauseker M, Voskanyan A, Fabarius A, Haferlach C, Hochhaus A, Saußele S. Impact of emerging ACA on survival in chronic myeloid leukemia (CML). Leukemia. 2022 Oct;36(10):2544-2547. doi: 10.1038/s41375-022-01681-3. Epub 2022 Aug 23. PMID: 35999258; PMCID: PMC9522580.
Breccia M, Chiodi F, Nardozza AP, Valsecchi D, Perrone V, Sangiorgi D, Giacomini E, Rendace MC, Coco P, Premoli E, Degli Esposti L. The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy. Adv Ther. 2023 Mar;40(3):961-974. doi: 10.1007/s12325-022-02398-6. Epub 2022 Dec 23. PMID: 36562943; PMCID: PMC9989002.
Assanto GM, Scalzulli E, Carmosino I, Martelli M, Breccia M. From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care. Expert Rev Hematol. 2022 Nov;15(11):963-971. doi: 10.1080/17474086.2022.2142112. Epub 2022 Nov 1. PMID: 36305791.
Puzzolo MC, Breccia M, Mariglia P, Colafigli G, Pepe S, Scalzulli E, Mariggiò E, Latagliata R, Guarini A, Foà R. Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation. J Clin Med. 2022 Sep 23;11(19):5594. doi: 10.3390/jcm11195594. PMID: 36233461; PMCID: PMC9570842.
Breccia M, Chiodi F, Nardozza AP, Valsecchi D, Perrone V, Sangiorgi D, Giacomini E, Rendace MC, Coco P, Premoli E, Degli Esposti L. Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy. J Clin Med. 2022 Jun 22;11(13):3597. doi: 10.3390/jcm11133597. PMID: 35806885; PMCID: PMC9267241
Houshmand M, Vitale N, Orso F, Cignetti A, Molineris I, Gaidano V, Sainas S, Giorgis M, Boschi D, Fava C, Passoni A, Gai M, Geuna M, Sora F, Iurlo A, Abruzzese E, Breccia M, Mulas O, Caocci G, Castagnetti F, Taverna D, Oliviero S, Pane F, Lolli ML, Circosta P, Saglio G. Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. Cell Death Dis. 2022 Jun 30;13(6):576. doi: 10.1038/s41419-022-05028-9. PMID: 35773274; PMCID: PMC9247109.
Breccia M, Scalzulli E, Pepe S, Colafigli G, Martelli M. Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New Agents. Curr Cancer Drug Targets. 2022;22(10):796-805. doi: 10.2174/1568009622666220613144253. PMID: 35702772.
Iurlo A, Cattaneo D, Artuso S, Consonni D, Abruzzese E, Binotto G, Bocchia M, Bonifacio M, Castagnetti F, Galimberti S, Gozzini A, Iezza M, Latagliata R, Luciano L, Maggi A, Miggiano MC, Pregno P, Rege-Cambrin G, Russo S, Scortechini AR, Tafuri A, Tiribelli M, Fava C, Rosti G, Foa R, Breccia M, Saglio G. Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Front Oncol. 2022 Mar 3;12:839915. doi: 10.3389/fonc.2022.839915. PMID: 35311109; PMCID: PMC8927081.
Breccia M, Scalzulli E, Pepe S, Colafigli G, Bisegna ML, Capriata M, Martelli M. Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients. Expert Rev Hematol. 2022 Jan;15(1):25-32. doi: 10.1080/17474086.2022.2018296. Epub 2021 Dec 27. PMID: 34894984.
Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, Tiribelli M, Stagno F, Caocci G, Martino B, Luciano L, Pizzuti M, Gozzini A, Scortechini AR, Albano F, Bergamaschi M, Capodanno I, Patriarca A, Fava C, Rege-Cambrin G, Sorà F, Galimberti S, Bocchia M, Binotto G, Reddiconto G, DiTonno P, Maggi A, Sanpaolo G, De Candia MS, Giai V, Abruzzese E, Miggiano MC, La Barba G, Pietrantuono G, Guella A, Levato L, Mulas O, Saccona F, Rosti G, Musto P, Di Raimondo F, Pane F, Baccarani M, Saglio G, Ciccone G. Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Front Oncol. 2021 Aug 26;11:739171. doi: 10.3389/fonc.2021.739171. PMID: 34513714; PMCID: PMC8427308.
Mancini M, De Santis S, Monaldi C, Castagnetti F, Lonetti A, Bruno S, Dan E, Sinigaglia B, Rosti G, Cavo M, Gugliotta G, Soverini S. Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. Front Oncol. 2022 Aug 5;12:901132. doi: 10.3389/fonc.2022.901132. PMID: 35992847; PMCID: PMC9391055.
De Santis S, Monaldi C, Mancini M, Bruno S, Cavo M, Soverini S. Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia. Onco Targets Ther. 2022 Jan 25;15:103-116. doi: 10.2147/OTT.S289306. PMID: 35115784; PMCID: PMC8800859.
Naumann N, Bross-Bach U, Seifarth W, Fabarius A, Hofmann WK, Saußele S, Spiess B. A new aberrantly spliced BCR-ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia. EJHaem. 2022 Sep 2;3(4):1339-1342. doi: 10.1002/jha2.553. PMID: 36467807; PMCID: PMC9713225.
Saußele S, Kohlbrenner K, Vogelmann T, Schubert T. Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis. Oncol Res Treat. 2022;45(7-8):400-407. doi: 10.1159/000524284. Epub 2022 Mar 25. PMID: 35340007.
Machova Polakova K, Zizkova H, Zuna J, Motlova E, Hovorkova L, Gottschalk A,. Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission. Leukemia. 2020 Aug;34(8):2113-2124. doi: 10.1038/s41375-020-0882-1. Epub 2020 May 29. PMID: 32472084.
Back